Blocking proteins that turn on cancer genes in multiple myeloma
Targeting chromatin acetylation factors in multiple myeloma
This project tests new drug-like molecules that remove proteins helping myeloma cells grow, with the aim of leading to better treatments for adults with multiple myeloma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11291317 on NIH RePORTER |
What this research studies
Researchers are using lab-grown human myeloma cells and tumor models to see whether chemical 'degraders' that destroy the CBP and p300 proteins can stop cancer growth. They will compare these degraders to existing CBP/p300 inhibitors and use genomic and chromatin tests to track how gene activity and DNA packaging change. The team will also test dosing and drug combinations in mouse xenograft models to find approaches that shrink tumors. The work is focused on deciding if these degraders are promising candidates for future therapeutic development for patients.
Who could benefit from this research
Good fit: Adults with relapsed or treatment-resistant multiple myeloma could be candidates for future clinical trials testing CBP/p300 degraders.
Not a fit: Patients whose myeloma does not rely on CBP/p300-driven gene activation or who require immediate standard-of-care treatment are unlikely to benefit from this preclinical project.
Why it matters
Potential benefit: If successful, this could lead to new targeted therapies that more effectively shrink tumors or overcome resistance in multiple myeloma patients.
How similar studies have performed: Related CBP/p300 inhibitors have entered early clinical testing, but using protein degraders is a newer approach that remains largely preclinical.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Ott, Christopher J — Massachusetts General Hospital
- Study coordinator: Ott, Christopher J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.